1. Academic Validation
  2. The Central Analgesic Mechanism of YM-58483 in Attenuating Neuropathic Pain in Rats

The Central Analgesic Mechanism of YM-58483 in Attenuating Neuropathic Pain in Rats

  • Cell Mol Neurobiol. 2016 Oct;36(7):1035-43. doi: 10.1007/s10571-015-0292-5.
Zeyou Qi 1 Yaping Wang 2 Haocheng Zhou 1 Na Liang 1 Lin Yang 1 Lei Liu 1 Wei Zhang 1
Affiliations

Affiliations

  • 1 Second Xiang-Ya Hospital of Central South University, Changsha, China.
  • 2 Second Xiang-Ya Hospital of Central South University, Changsha, China. wangyaping5678@126.com.
Abstract

Calcium Channel antagonists are commonly used to treat neuropathic pain. Their analgesic effects rely on inhibiting long-term potentiation, and neurotransmitters release in the spinal cord. Store-operated CA(2+)channels (SOCCs) are highly CA(2+)-selective cation channels broadly expressed in non-excitable cells and some excitable cells. Recent studies have shown that the potent inhibitor of SOCCs, YM-58483, has analgesic effects on neuropathic pain, but its mechanism is unclear. This experiment performed on spinal nerve ligation (SNL)-induced neuropathic pain model in rats tries to explore the mechanism, whereby YM-58483 attenuates neuropathic pain. The left L5 was ligated to produce the SNL neuropathic pain model in male Sprague-Dawley rats. The withdrawal threshold of rats was measured by the up-down method and Hargreaves' method before and after intrathecal administration of YM-58483 and vehicle. The SOCCs in the spinal dorsal horn were located by immunofluorescence. The expression of phosphorylated ERK and phosphorylated CREB, CD11b, and GFAP proteins in spinal level was tested by Western blot, while the release of proinflammatory cytokines (IL-1β, TNF-α, PGE2) was measured by enzyme-linked immunosorbent assay (ELISA). Intrathecal YM-58483 at the concentration of 300 μM (1.5 nmol) and 1000 μM (10 nmol) produced a significant central analgesic effect on the SNL rats, compared with control + vehicle (n = 7, P < 0.001). However, both could not prevent the development of neuropathic pain, compared with normal + saline (P < 0.001). Immunofluorescent staining revealed that Orai1 and STIM1 (the two key components of SOCCs) were located in the spinal dorsal horn neurons. Western blot showed that YM-58483 could decrease the levels of P-ERK and P-CREB (n = 10, #P < 0.05), without affecting the expression of CD11b and GFAP (n = 10, #P > 0.05). YM-58483 also inhibited the release of spinal cord IL-1β, TNF-α, and PGE2, compared with control + vehicle (n = 5, #P < 0.001). The analgesic mechanism of YM-58483 may be via inhibiting central ERK/CREB signaling in the neurons and decreasing central IL-1β, TNF-α, and PGE2 release to reduce neuronal excitability in the spinal dorsal horn of the SNL rats.

Keywords

Neuronal excitability; Neuropathic pain; Proinflammatory factor; SOCCs; Spinal cord dorsal horn.

Figures
Products